Annals of Surgical Oncology

, Volume 26, Issue 2, pp 694–696 | Cite as

Completion Thyroidectomy: Revisited a Quarter of a Century Later

  • Benzon M. DyEmail author
  • Veljko Strajina
  • Michael Tuttle
  • Ashok R. Shaha
Endocrine Tumors

The excellent outcome for patients with thyroid cancer is increasingly recognized, with Japan and the United States considerably interested in observing selected microcarcinomas.1,2 In the last decade, our experience has shown that most thyroid microcarcinomas can be observed safely.3 It therefore is understandable why the potential overtreatment of thyroid cancer has been debated, not only among professionals, but also in the media and general public.

The complications of thyroidectomy may be worse than the thyroid cancer itself, and the complications are directly related to the extent of surgery. Even experienced surgeons report a 1% rate of permanent hypoparathyroidism when both thyroid lobes are removed.47Conversely, this complication is virtually unknown after thyroid lobectomy. Some patients may require thyroid hormone supplementation after thyroid lobectomy, but it appears to be tolerated much better than full replacement, which is needed after total thyroidectomy. Certain...


  1. 1.
    Ito Y, Miyauchi A, Inoue H, et al. An observational trial for papillary thyroid microcarcinoma in Japanese patients. World J Surg. 2010;34:28–35.CrossRefPubMedGoogle Scholar
  2. 2.
    Ito Y, Miyauchi A, Kihara M, Higashiyama T, Kobayashi K, Miya A. Patient age is significantly related to the progression of papillary microcarcinoma of the thyroid under observation. Thyroid. 2014;24:27–34.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Tuttle RM, Fagin JA, Minkowitz G, et al. Natural history and tumor volume kinetics of papillary thyroid cancers during active surveillance. JAMA Otolaryngol Head Neck Surg. 2017;143:1015–20.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Ritter K, Elfenbein D, Schneider DF, Chen H, Sippel RS. Hypoparathyroidism after total thyroidectomy: incidence and resolution. J Surg Res. 2015;197:348–53.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Asari R, Passler C, Kaczirek K, Scheuba C, Niederle B. Hypoparathyroidism after total thyroidectomy: a prospective study. Arch Surg. 2008;143:132–7; discussion 138.Google Scholar
  6. 6.
    Su A, Wang B, Gong Y, Gong R, Li Z, Zhu J. Risk factors of hypoparathyroidism following total thyroidectomy with central lymph node dissection. Med Baltimore. 2017;96:e8162.CrossRefGoogle Scholar
  7. 7.
    Kim SM, Kim HK, Kim KJ, et al. Recovery from permanent hypoparathyroidism after total thyroidectomy. Thyroid. 2015;25:830–33.CrossRefPubMedGoogle Scholar
  8. 8.
    Shaha AR, Jaffe BM. Completion thyroidectomy: a critical appraisal. Surgery. 1992;112:1148–52; discussion 1152–43.Google Scholar
  9. 9.
    Bilimoria KY, Bentrem DJ, Ko CY, et al. Extent of surgery affects survival for papillary thyroid cancer. Ann Surg. 2007;246:375–81; discussion 381–74.Google Scholar
  10. 10.
    Hay ID, Grant CS, Bergstralh EJ, Thompson GB, van Heerden JA, Goellner JR. Unilateral total lobectomy: is it sufficient surgical treatment for patients with AMES low-risk papillary thyroid carcinoma? Surgery. 1998;124:958–64; discussion 964–56.Google Scholar
  11. 11.
    Adam MA, Pura J, Goffredo P, et al. Impact of extent of surgery on survival for papillary thyroid cancer patients younger than 45 years. J Clin Endocrinol Metab. 2015;100:115–21.CrossRefPubMedGoogle Scholar
  12. 12.
    Nixon IJ, Ganly I, Patel SG, et al. Thyroid lobectomy for treatment of well-differentiated intrathyroid malignancy. Surgery. 2012;151:571–79.CrossRefPubMedGoogle Scholar
  13. 13.
    Duren M, Siperstein AE, Shen W, Duh QY, Morita E, Clark OH. Value of stimulated serum thyroglobulin levels for detecting persistent or recurrent differentiated thyroid cancer in high- and low-risk patients. Surgery. 1999;126:13–9.CrossRefPubMedGoogle Scholar
  14. 14.
    Mazzaferri EL. An overview of the management of papillary and follicular thyroid carcinoma. Thyroid. 1999;9:421–27.CrossRefPubMedGoogle Scholar
  15. 15.
    Nixon IJ, Patel SG, Palmer FL, et al. Selective use of radioactive iodine in intermediate-risk papillary thyroid cancer. Arch Otolaryngol Head Neck Surg. 2012;138:1141–46.CrossRefPubMedGoogle Scholar
  16. 16.
    Hay ID, Hutchinson ME, Gonzalez-Losada T, et al. Papillary thyroid microcarcinoma: a study of 900 cases observed in a 60-year period. Surgery. 2008;144:980–7; discussion 987–8.Google Scholar
  17. 17.
    Hay ID, Thompson GB, Grant CS, et al. Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940–1999): temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients. World J Surg. 2002;26:879–85.CrossRefPubMedGoogle Scholar
  18. 18.
    Hay ID, Bergstralh EJ, Goellner JR, et al. Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery. 1993;114:1050–57; discussion 1057–58.Google Scholar
  19. 19.
    Shaha AR, Loree TR, Shah JP. Intermediate-risk group for differentiated carcinoma of thyroid. Surgery. 1994;116:1036–40; discussion 1040–31.Google Scholar
  20. 20.
    Cady B, Rossi R. An expanded view of risk-group definition in differentiated thyroid carcinoma. Surgery. 1988;104:947–53.PubMedGoogle Scholar
  21. 21.
    Cranshaw IM, Carnaille B. Micrometastases in thyroid cancer: an important finding? Surg Oncol. 2008;17:253–58.CrossRefPubMedGoogle Scholar
  22. 22.
    Chow SM, Law SC, Chan JK, Au SK, Yau S, Lau WH. Papillary microcarcinoma of the thyroid: prognostic significance of lymph node metastasis and multifocality. Cancer. 2003;98:31–40.CrossRefPubMedGoogle Scholar
  23. 23.
    Lang BH, Lo CY, Chan WF, Lam KY, Wan KY. Staging systems for papillary thyroid carcinoma: a review and comparison. Ann Surg. 2007;245:366–78.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Paphavasit A, Thompson GB, Hay ID, et al. Follicular and Hurthle cell thyroid neoplasms: is frozen-section evaluation worthwhile? Arch Surg. 1997;132:674–78; discussion 678–80.Google Scholar
  25. 25.
    Udelsman R, Westra WH, Donovan PI, Sohn TA, Cameron JL. Randomized prospective evaluation of frozen-section analysis for follicular neoplasms of the thyroid. Ann Surg. 2001;233:716–22.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    American Thyroid Association Guidelines Taskforce on Thyroid N, Differentiated Thyroid C, Cooper DS, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19:1167–214.Google Scholar

Copyright information

© Society of Surgical Oncology 2018

Authors and Affiliations

  • Benzon M. Dy
    • 1
    Email author
  • Veljko Strajina
    • 2
  • Michael Tuttle
    • 3
  • Ashok R. Shaha
    • 3
  1. 1.Mayo Clinic, Breast, Endocrine, Metabolic and GI SurgeryRochesterUSA
  2. 2.Mayo Clinic, SurgeryRochesterUSA
  3. 3.Department of Head and Neck SurgeryMemorial Sloan-Kettering Cancer CenterNew YorkUSA

Personalised recommendations